

FY1920 Q1 Performance in Delivering

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
16/LO/1820	212826	Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa	Number Agreed	3	3	Date Agreed	31/03/2018	3	21/08/2018	5	Recruitment Finished
17/YH/0329	216857	A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease	Number Agreed	6	6	Date Agreed	04/02/2019	0	05/04/2019	0	Withdrawn By Sponsor
18/LO/0731	246135	The Effects of Psilocybin on Cognitive Function in Healthy Participants	Number Agreed	90	90	Date Agreed	25/04/2019	90	30/04/2019	90	Recruitment Finished